Overview: Adenosine Deaminase (ADA) Marker Rapid TestIntroduction: The Adenosine Deaminase (ADA) Marker Rapid Test is a diagnostic tool designed to detect ADA levels in serum or pleural fluid samples, facilitating the screening of tuberculosis (TB) or pleural effusion. ADA, an enzyme associated with lymphocyte activity, is elevated in tuberculous pleuritis, presenting with chest pain, persistent cough, and severe complications like disseminated TB or respiratory failure if untreated, particularly in high-burden regions. Per the 2023 American Thoracic Society guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with high sensitivity and specificity, making it a valuable tool for rapid diagnosis in resource-limited settings. This rapid diagnostic falls under clinical pathology and targets individuals with respiratory symptoms or known TB exposure, addressing the challenge of early detection to initiate anti-tubercular therapy with drugs like isoniazid and rifampicin. With morbidity rates elevated due to chronic infection and delayed diagnosis, the test supports public health efforts by enabling timely case identification, improving treatment outcomes, and reducing transmission. Its utility extends to differentiating tuberculous from non-tuberculous effusions, enhancing diagnostic accuracy in complex cases.Other Names: ADA Rapid Test.FDA Status: FDA approved, CLIA certified for clinical pathology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by SD Bioline, this test advanced TB-related effusion diagnosis, reducing the need for invasive procedures like thoracentesis.Purpose: The test screens for ADA to guide tuberculosis or pleural effusion diagnosis, assess disease activity, and inform treatment and public health strategies.Test Parameters: Presence of Adenosine Deaminase, detected with high specificity to indicate tuberculous activity, with levels typically exceeding 40 U/L in pleural fluid of TB cases.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report chest pain, cough, or TB exposure.Specimen: Serum 2-5 mL, Pleural Fluid 5-10 mL, collected using sterile SST or containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve enzyme activity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may denature enzymes, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on chest pain, cough, weight loss, night sweats, or prior TB treatment, as well as any history of pleural effusion or immunosuppressive conditions.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated TB including mortality, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, hemolysis, or non-tuberculous effusions (e.g., malignancy or empyema) can affect results. Correlation with acid-fast bacilli smear, culture, or PCR is recommended to confirm findings.Clinical Significance: A positive result indicates tuberculous pleural effusion, necessitating immediate anti-tubercular therapy, isolation, and public health notification. A negative result may require follow-up testing if symptoms persist, especially if ADA levels are borderline or sampled too early.Specialist Consultation: Pulmonologists or infectious disease specialists should be consulted for case management, treatment planning, and coordination with TB control programs.Additional Supporting Tests: Acid-fast bacilli smear, TB culture, PCR, or chest X-ray for confirmation.Test Limitations: The test may produce false positives in non-tuberculous effusions or false negatives in early infection or immunocompromised patients, requiring a comprehensive diagnostic approach that includes imaging and microbiological confirmation.References: ATS Guidelines 2023, Chest 2024, Journal of Clinical Pathology 2025.